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Abstract Fructans from agave have received specific atten-
tion because of their highly branched fructan content.We have
previously reported that the degree of polymerization (dp)
influences their biological activity. Therefore, the aim of this
study was to investigate the effect of unfractionated and frac-
tionated fructans (higher and lower dps) from Agave tequilana
in high-fat diet-induced (HFD) obese mice. Fructans with a
lower dp (HFD+ScF) decreased weight gain by 30%, body fat
mass by 51 %, hyperglycemia by 25 % and liver steatosis by
40 %. Interestingly, unfractionated fructans (HFD+F) de-
creased glucose and triglycerides (TG), whereas fractionated
fructans with a higher dp (HFD+LcF) decreased TG but not
glucose; in contrast, HFD+ScF decreased glucose but not TG.
Our findings suggest that both higher and lower dp agave
fructans have complementary effects in metabolic disorders
related to obesity. These findings may contribute to the devel-
opment of improved food supplements with a specific ratio
combination of fructans with different dps.




dp Degree of polymerization
F Total fructans
HFD High-fat diet
LcF Fructans with a higher dp
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Dietary fibers, such as inulin-type fructans, are selectively
used and fermented by the gut, and several studies have dem-
onstrated their health benefits [1–4]. For example, these non-
digestible carbohydrates have been demonstrated to reduce
weight gain and related metabolic disorders via specific ac-
tions on food intake [5–7]. Most of these findings have been
obtained following supplementation with inulin-type fructans
from Jerusalem artichoke (Helianthus tuberosus) and chicory
(Cichorium intybus) [8]. The inulin from these sources com-
prises linear chains of β (2–1) fructans (unbranched).
Interestingly, Agave tequilana Weber var. azul contains com-
plex fructans with demonstrated bioactivity. These fructans
are highly branched with both beta (2–1) and beta (2–6) link-
ages [9, 10]. Moreover, they are resistant to hydrolysis by
human digestive enzymes and may be fermented by colonic
microbiota; however, their mode of action is not completely
elucidated. Fructans from Agave tequilana and Agave
angustifolia have been primarily investigated as a complex
mix of different chain lengths (total fructans). C57Bl/6J mice
fed a standard diet supplemented with fructans from Agave
tequilana Gto., exhibited reduced food intake, body weight
and plasma glucose and lipids [11]. In diabetic rats with nor-
mal weight, fructans from Agave angustifolia diminished hy-
perglycemia and liver steatosis [12]. A previous study con-
ducted in our laboratory demonstrated that both the degree of
polymerization (dp) and the demineralization process influ-
ence the biological activity of agave fructans. Our studies
indicate that the treatment of obese mice with fructans with a
lower dp (dp < 10) from A. tequilana did not increase the
count of fecal Bifidobacteria; however, it reduced body
weight. In contrast, obese mice that received total fructans
exhibited an increased fecal Bifidobacteria count; however,
they did not exhibit changes in the lipid profile or body weight
[13]. It was subsequently reported that agavins (agave
fructans) with a lower dp from A. angustifolia and
A. potatorum promoted the release of peptides involved in
appetite regulation and may thus be involved in the control
of obesity and its associated metabolic disorders [14]. On this
basis, the present study aimed to investigate the effect of
unfractionated and fractionated fructans (higher and lower
dp) from Agave tequilana in high-fat diet-induced obese mice.
Materials and Methods
Agave Fructan Extraction, Purification and Carbohydrate
Profile Characterization Agave tequilana Weber var. azul
plants were collected from an endemic growing area in
Tequila, Jalisco, Mex. The collection, purification and charac-
terization were performed as previously described [13]. The
total contents of the fructans were labeled F, whereas two
fractions of fructans with different dp profiles were obtained
via ultrafiltration procedures. Agave fructans with a higher dp
>10 (labeled LcF) were obtained from the retentate of a 3 kDa
membrane, whereas fructans with a lower dp < 10 (labeled
ScF) were recovered from the retentate of a 1 kDa membrane.
Animals, Diets and Experimental Groups Sixty male mice
(C57/BL/6) with body weights of 20–25 g (Harlan/Envigo
Inc.) were housed in a controlled environment with free access
to food and water. After one week of acclimatization, the mice
were randomly divided into two experimentation groups. A)
Model validation; with two groups (n = 10/group): 1) was fed
a standard diet (SD) with 18 % fat (energy density 3.1 kcal/g),
and 2) was fed a high fat diet (HFD) with 60 % fat (energy
density 5.1 kcal/g), both for eight weeks (20128S and
TD.6414 diets, respectively, from Teklad Harlan/Envigo
Inc.). B) Treatments; with four groups (n = 10/group): 3)
Orafti sinergy1TM (HFD+OS1), unbranched inulin-type
fructans from chicory, 4) unfractionated agave fructans
(HFD+F) and fractionated, 5) agave fructans with a higher
dp (HFD+LcF) and 6) a lower dp (HFD+ScF). The mice
had free access to the HFD or SD in common cages (five
per cage); however, they were orally administered with
fructans at doses of 125 mg / 25 g of body weight individually
three times perweek for eight weeks. The study was approved
by the local Animal Care and Use Committee and complied
with local (NOM-062-ZOO-1999) and International
Guidelines (Animal Welfare Assurance A5281-01).
Biochemical Assays The fasting glucose concentration was
determined from tail vein blood using a hand-held glucometer,
ONETOUCH® ULTRA®, with reactive strips (Johnson &
Johnson). At the end of the experiment, the total cholesterol
(TC), triglycerides (TG), high-density lipoproteins (HDL),
low-density lipoproteins (LDL), very low-density lipoproteins
(VLDL) and hepatic enzymes AST and ALT were measured
via automated enzymatic methods on a Sincron-7 analyzer.
Oral Glucose Tolerance Test An oral glucose tolerance test
was performed on 6 h fasting-mice [15]. In brief, the mice
were administered glucose via gavage (1 g/kg glucose, 20 %
glucose solution). The blood glucose was determined using
reactive strips on a glucose meter from whole blood drawn
from the tail-tip capillary region at points 0, 30, 60 and
120 min after gavage.
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Fat Pad Collection and Liver Histology The mice were
sacrificed via an i.p. injection with ketamine / xylazine
(100/10 mg / kg). White adipose tissues were dissected
and weighed. Liver tissues were stained with hematox-
ylin and eosin and observed under a light microscope
(Leica, DMR). Biopsies were classified into three grades
[16], in which a sample is classified as grade 1 when
fat vacuoles are identified in 5–33 % of hepatocytes,
grade 2 when 33–66 % of hepatocytes are affected by
fat vacuoles, and grade 3 when fat vacuoles are identi-
fied in >66 % of hepatocytes.
Data AnalysesA Kolmogorov-Smirnov test was performed
for all data to determine whether the values originate from
a Gaussian distribution. In the first experiment BModel
validation^, statistical differences between groups were
assessed using unpaired t-tests two-tailed, whereas for the
second experiment BTreatments^, statistical differences be-
tween groups were assessed using one-way ANOVA
followed by a Dunnett post-hoc test to compare all treat-
ments vs. HDF with GraphPad Prism 5 Software, Inc.,
USA. Differences were considered significant at p ≤ 0.05.
The obtained data are expressed as the mean ± standard
deviation (mean ± SD).
Results and Discussion
A limited number of studies have utilized branched fructans
from agave. These studies were primarily designed to analyze
the prebiotic effects from agave fructans in in vitro studies
[17–21], animal models [13, 22, 23] and clinical trials
[24–27], whereas other studies have investigated the effects
on food intake, body weight gain and hyperglycemia [11, 14,
22, 28]. Only one study has been conducted to analyze liver
steatosis in diabetic rats supplemented with agave fructans
[12], and several studies have been designed to investigate
the relationship between dp and biological activity [13, 20,
21]. Thus, our study aimed to investigate the effect of
unfractionated and fractioned branched fructans (higher and
lower dp) from Agave tequilana in HFD induced obese mice
and compare them with unbranched –linear- chicory fructans.
As expected, the final body weight, weight gain and fat mass
in the mice fed a HFD were increased (p < 0.05) compared
with the mice fed a SD (supplementary file 1). The weight
gain in the HFD was approximately 10 g more than the SD,
whereas the fat mass was increased more than 10-fold. The
obese mice accumulated more epididymal (1.86 g) and sub-
cutaneous (1.78 g) fat compared with visceral fat (0.68 g). The
mice fed a SD attained a total fat accumulation of 0.34 g,
whereas the mice fed a HFD accumulated 4.32 g (11.7-fold,
Table 1 Effects of fructans on
weight gain, body fat, lipid profile
and liver enzymes in mice fed a






HFD HFD + OS1 HFD + F HFD + LcF HFD + ScF
Final body weight (g) 36.71 ± 1.5 36.55 ± 3.6 35.52 ± 3.7 37.49 ± 4.2 33.5 ± 2.2*
Gain weight (g) 16.37 ± 2.0 13.26 ± 1.0 12.54 ± 0.82 11.92 ± 1.2 8.96 ± 0.42*
Fat Mass (g) 4.32 ± 0.25 3.82 ± 0.62 4.48 ± 0.37 4.20 ± 0.42 2.28 ± 0.52*
Epididymal (g) 1.86 ± 0.10 1.68 ± 0.30 1.85 ± 0.14 2.04 ± 0.21 1.04 ± 0.15*
Visceral (g) 0.67 ± 0.03 0.62 ± 0.09 0.51 ± 0.05 0.65 ± 0.06 0.42 ± 0.11
Subcutaneous (g) 1.78 ± 0.18 1.50 ± 0.25 1.19 ± 0.11 1.50 ± 0.15 0.71 ± 0.19*
Triglycerides (mg/dl) 196.0 ± 60.4 136.6 ± 8.8 95.0 ± 5.5* 92.6 ± 5.2* 129.6 ± 9.8
Total cholesterol (mg/dl) 147.6 ± 8.5 140.0 ± 13.0 151.3 ± 2.1 145.6 ± 5.2 124.3 ± 3.1
HDL (mg/dl) 71.3 ± 10.9 80.0 ± 5.0 79.3 ± 4.0 70.6 ± 8.7 55.3 ± 8.5
LDL (mg/dl) 37.0 ± 10.6 32.67 ± 10.4 53.0 ± 2.6 56.3 ± 14.1 43.3 ± 9.3
VLDL (mg/dl) 39.3 ± 11.9 27.3 ± 1.6 19.0 ± 1.1 18.6 ± 0.8 25.6 ± 2.0
Glucose (mg/dl) 171.0 ± 17.1 139.1 ± 19.5* 137.1 ± 14.11* 160.4 ± 20.5 129.1 ± 22.4*
AST (U/l) 159.0 ± 9.6 134.6 ± 22.5 146.6 ± 28.3 101.6 ± 21.2 66.3 ± 8.5*
ALT (U/l) 64.6 ± 9.6 51.3 ± 11.6 46.3 ± 4.4 52.3 ± 1.4 47.0 ± 2.3
Mean ± SD, growth parameters n = 10, biochemical parameters n = 6. * p < 0.05
Abbreviations: ALT alanine aminotransferase, ASTaspartate aminotransferase, F total fructans,HFD high-fat diet,
HDL high-density lipoproteins, LcF fructans with higher dp, LDL low-density lipoproteins, OS1 Orafti sinergy1,
ScF fructans with lower dp, SD standard-diet, VLDL very low-density lipoproteins
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compared with the mice fed a SD). The blood glucose, TG,
TC and AST concentrations of the HFD mice were also in-
creased (p < 0.05) compared with the SD mice. Finally, the
mice fed a HFD exhibited substantially increased blood glu-
cose, 60 mg/dl more than the SD, whereas the TG and TC
increases were 100 and 80mg / dl, respectively. Commercially
inulin-type fructans from chicory (unbranched fructans) were
used as a reference because they have been extensively inves-
tigated as prebiotics and may be used to compare branched
fructans from agave. However, we did not identify statistically
significant differences in the weight gain, fat mass, lipid pro-
file or transaminases in the obese mice treated with un-
branched fructans (HFD+OS1) (Table 1). Fructans from
Agave tequilana with a lower dp (HFD+ScF) decreased (p ≤
0.05) the final body weight (Table 1, Fig. 1a and b), weight
gain and fat mass (Table 1). These animals exhibited a weight
difference of 7.4 g compared with the HFD, which represents
a decrease of 30 % in the body weight gain. HFD+ScF also
accumulated 51% less fat compared with the mice fed a HFD,
which resulted in 2.28 g of total fat. We identified a positive
linear correlation between the weight increase and fat pad
accumulation in all treatments (Fig. 1c) with an R2 of
0.9535; however, the HFD+ScF showed reduced (p ≤ 0.05)
epididymal and subcutaneous fat even if they were
simultaneously fed a HFD. These findings indicate that ScF
from Agave tequilana significantly reduces body weight gain
by diminishing fat accumulation in obese mice. In contrast,
unfractionated agave fructans (HFD+F) and agave fructans
with a higher dp (HFD+LcF) did not exhibit statistical differ-
ences in body weight, weight gain or fat mass; however, TG
decreased (p ≤ 0.05). Fructan supplementation with inulin-
type fructans from chicory (HDF+OS1), unfractionated
fructans (HFD+F) and fractionated fructans with a lower dp
from agave (HFD+ScF) decreased (p ≤ 0.05) glucose and the
area under the curve (AUC) in the oral glucose tolerance test
(between 14 and 45 %) compared with the AUC of the obese
mice fed a HFD. The obese mice exhibited a concentration of
171 mg / dl, whereas treatment with fructans from chicory
(HFD+OS1) decreased hyperglycemia by 19 % (139 mg /
dl), the treatment with agave unfractionated fructans (HFD+
F) decreased hyperglycemia by 20 % (137 mg/dl) and frac-
tionated fructans with lower dp (HFD+ScF) decreased hyper-
glycemia by 25% (129mg / dl) and the AUCwas 24,375 units
compared with 27,000 units in the obese mice fed a HFD
(Table 1, Fig. 1d and e). In summary, unbranched fructans
reduced glycemia; however, there was no change in the serum
cholesterol and TG levels. Similar results have been demon-
strated in dietary supplementation with inulin in rats fed a






















































































































Fig. 1 Growth performance and glycemia. Final weight (a), body weight
kinetics (b), correlation of gain weight and body fat (c), glucose tolerance
test and AUC (d and e) in mice fed a HFD and supplemented with
fructans: chicory fructans (OS1), agave fructans unfractionated (F) and
fractionated in a higher dp (LcF) and lower dp (ScF). Data are presented
as the mean ± SD (n = 10). The asterisk (*) denotes a significant
difference compared with a HFD (p < 0.05)
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HFD [7]. Moreover, the mice fed branched fructans from
A. tequilana with a lower dp (HFD+ScF) decreased body
weight gain by 30 %, body fat mass by 51 % and glycemia
by 25 %. Interestingly, unfractionated branched fructans
(HFD+F) decreased blood glucose and TG, whereas fraction-
ated fructans with a higher dp (HFD+LcF) decreased TG but
not glucose; moreover, fructans with a lower dp (HFD+ScF)
decreased blood glucose but not TG. Linear fructans from
chicory exhibited similar effects on glucose to unfractionated
branched fructans from agave. These findings may explain the
evidence regarding reductions in weight gain and blood glu-
cose concentration in different animal models supplemented
with total fructans from Agave spp., including non-obese mice
[11, 14], diabetic rats [12] and a hypercholesterolemic model
[28]. C57BL/6J male mice fed a HFD share nearly the same
human obesity phenotype; visceral adiposity, hyperglycemia,
insulin and leptin resistance, as well as hepatic steatosis [29,
30]. In this study, the liver steatosis grades were affected by
fructan supplementation (supplementary file 2). Treatment
with unbranched fructans from chicory (HFD+OS1) reduced
accumulated fat droplets (macrovesicular), which decreased
the steatosis percentage (20 %) similar to the animals supple-
mented with fructans from agave with a higher dp (HFD+
LcF). Moreover, treatment with unfractionated fructans
(HFD+F) exhibited a less decrease in the degree of steatosis
(10 %). The most interesting results were identified in the
mice treated with fructans from agave with a lower dp
(HFD+ScF) , which ind ica ted reduced s tea tos i s
(microvesicular) (40 %) with minimal inflammatory invasions
and few hypertrophic hepatocytes (grade 1) compared with
the untreated mice (HFD) with moderate steatosis (grade 2).
These findings are consistent with the reduction in AST levels
presented in Table 1 and could explain why liver steatosis
decreased in diabetic rats supplemented with fructans from
Agave angustifolia as previously reported [12]. Bacteria grew
according to the molecular weight of the agave fructans [20],
in which fructans with a higher dp exert a more pronounced
prebiotic effect [31] in contrast to fructans with a lower dp that
exhibit more anti-obesity effects [12, 13].
Conclusions
Our findings suggest that branched fructans from agave with a
lower dp are responsible for most of the beneficial effects
exerted by unfractionated fructans and represent a powerful
tool to prevent body weight gain, fat accumulation, liver
steatosis and hyperglycemia, despite high fat diet consump-
tion. However, both higher and lower dp agave fructans have
complementary effects in metabolic disorders related to obe-
sity. A high concentration of lower dp fructans is required to
achieve a reduction in weight gain and liver steatosis.
Therefore, it would be desirable to have agave branched
fructans in a specific ratio of higher and lower dp to achieve
positive effects in all metabolic disorders related to obesity,
and studies on this effective ratio should be performed.
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